In this new paper, published in Molecular Therapy Methods & Clinical Development, we highlight a recent project on the manufacture of adeno-associated virus (AAV) for gene therapy applications using a closed, semi-automated hollow-fibre bioreactor.
Many current methods for AAV production using adherent approaches are suboptimal due to their reliance on manual processing and manufacturing footprint. This paper highlights the benefits of using a closed and automated bioreactor system, reducing production times, operating costs and process risk.
